Type stringclasses 2
values | Section_id stringclasses 4
values | Primary_id stringlengths 11 11 | Secondary_id stringlengths 0 11 | Statement stringlengths 34 385 | Label stringclasses 2
values | Primary_evidence_index listlengths 1 65 | Secondary_evidence_index listlengths 0 73 | Primary_ct stringlengths 1.11k 16.3k | Secondary_ct stringlengths 101 16.3k | __index_level_0__ stringlengths 36 36 |
|---|---|---|---|---|---|---|---|---|---|---|
Comparison | Results | NCT01855828 | NCT00696072 | the secondary trial uses Overall Survival (OS) as outcome measurement, which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT01855828', 'Intervention': ['INTERVENTION 1: ', ' Chemo Plus Pertuzumab,Trastuzumab', ' During weeks 1-12, patients will receive pertuzumab, trastuzumab, and paclitaxel at the same time; during weeks 13-24 patients will receive pertuzumab and trastuzumab at the same time with 5-fluorouracil,... | {'Clinical Trial ID': 'NCT00696072', 'Intervention': ['INTERVENTION 1: ', ' Dasatinib Plus Letrozole', ' Dasatinib + Letrozole: Tablets, Oral, once daily, up to 2 years', ' Dasatinib 100 mg + Letrozole 2.5 mg', ' Patients on letrozole plus dasatinib received both drugs until progressive disease (PD) or intolerable ... | 6214280f-f665-48d3-b33f-9d798deff71f |
Single | Results | NCT00089999 | In total more participants in the primary trial had no tumor Response, than partial response, and 0 participants had a complete response. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT00089999', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib 1500 mg QD', ' Participants received lapatinib 1500 mg orally QD. Treatment was continued for 12 weeks or until disease progression or withdrawal from treatment for another reason. After Week 12, participants with clinical benefit h... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 108b54a9-b5cc-4f31-956f-e4e2e653d756 | |
Comparison | Results | NCT00723125 | NCT00617942 | 57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery, compared to 60% in cohort 1 of the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | {'Clinical Trial ID': 'NCT00723125', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1', ' Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over ... | {'Clinical Trial ID': 'NCT00617942', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1', '[Not Specified]', 'INTERVENTION 2: ', ' Cohort 2', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' Histologically documented adenocarcinoma of the breast', ' ANC > 1000 cells', ' Female; age > 18; Zubrod PS 0-1', '... | 662f4992-0155-4a82-926f-b1821539aab7 |
Comparison | Adverse Events | NCT01091454 | NCT00054275 | There were more cases of Anemia and Leukopenia in the primary trial than the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | {'Clinical Trial ID': 'NCT01091454', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Cisplatin and Brostallicin)', ' Patients receive 50 mg/m^2 cisplatin IV over 2 hours on day 1 and 10 mg/m^2 brostallicin IV over 10 minutes on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptabl... | {'Clinical Trial ID': 'NCT00054275', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel and OSI-774', ' docetaxel IV over 1 hour once weekly for 3 weeks and oral erlotinib once daily'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed stage IV or recurrent adenocarcinoma of the breast', ' Measur... | 398f744b-97cf-4f95-b162-99ec6652d327 |
Single | Intervention | NCT00632489 | the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib, whereas the dose of Capecitabine changes with Body surface area. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00632489', 'Intervention': ['INTERVENTION 1: ', ' LBH589 With Capecitabine', ' MTD, LBH589 with Capecitabine', ' LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 43421f19-878e-46f7-b456-8031835af649 | |
Single | Results | NCT02260531 | the percentage of participants achieving complete response (CR) or partial response (PR) was much lower in the HER2-positive group in the primary trial,than in the ER+ and/or PR+ group. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT02260531', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1 - Cabozantinib, Trastuzumab for HER2+', ' HER2-positive', ' Cabozantinib- orally administered daily per treatment cycle', ' Trastuzumab- IV administered once per cycle', ' MRI- Baseline, Cycle 2 Day 1, and every 2 cycles', ' Magn... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 13fa44e7-38be-48fb-a0eb-6b212549f526 | |
Single | Results | NCT02308020 | There were no participants in cohort 1 of the primary trial with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT02308020', 'Intervention': ['INTERVENTION 1: ', ' Part A Abemaciclib: HR+, HER2+ Breast Cancer', ' Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants wit... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 12ae2315-cc50-43ac-a595-762c85c1ec58 | |
Comparison | Adverse Events | NCT02536339 | NCT00371345 | Respiratory illnesses were observed in most of the patients in the primary trial and the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | {'Clinical Trial ID': 'NCT02536339', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab + Trastuzumab', ' Participants with CNS metastases secondary to HER2-positive MBC, who had disease progression in the brain following previous treatment with radiotherapy (whole-brain radiation therapy or stereotactic radiosurgery)... | {'Clinical Trial ID': 'NCT00371345', 'Intervention': ['INTERVENTION 1: ', ' Her2/Neu-amplified Tumor, 70 mg Twice Daily (BID) Dasatinib', ' Participants with a Human epidermal growth factor (Her2/neu)-amplified tumor type (defined as 3+ by immunohistochemistry [IHC] or positive by fluorescent or chromogenic in situ h... | 11403f92-661b-4334-8dfb-098586610ec6 |
Single | Intervention | NCT01422408 | the primary trial is a phase II trial in which all participants will recieve topical fluocinonide 0.05% face cream twice daily for two weeks. | Contradiction | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT01422408', 'Intervention': ['INTERVENTION 1: ', ' Supportive Care (Fluocinonide Cream)', ' This is a single-arm, single-stage, open-label phase II trial of topical fluocinonide 0.05% cream to improve vaginal symptoms.', ' All subjects will receive topical fluocinonide 0.05% cream to apply t... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2823adfc-b3a4-4626-9690-0c292aa8da04 | |
Comparison | Intervention | NCT02504424 | NCT03708393 | the primary trial and the secondary trial do not have the same number of study groups. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT02504424', 'Intervention': ['INTERVENTION 1: ', ' AeroForm Tissue Expander', ' AeroForm Tissue Expansion inflation with carbon dioxide by remote control', ' AeroForm Tissue Expander: The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by rem... | {'Clinical Trial ID': 'NCT03708393', 'Intervention': ['INTERVENTION 1: ', ' IUS Alone', 'IUS alone imaging', 'INTERVENTION 2: ', ' Imagio (IUS+OA)', 'IUS+OA imaging'], 'Eligibility': ['Inclusion Criteria:', ' - Female subjects participating in the PIONEER-0 Study of the Imagio Breast Imaging System with known clinic... | 1cda051f-27d0-4027-94cf-7b5340173ca2 |
Comparison | Results | NCT00435409 | NCT00319254 | The patient with the shortest PFS was in the secondary trial, at only 5 days, and the longest recorded PFS was in the primary trial at 78 months. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | {'Clinical Trial ID': 'NCT00435409', 'Intervention': ['INTERVENTION 1: ', ' Sunitinib + Capecitabine', ' Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous regimen. Capecitabine administered orally at a starting dose of 2000 mg/m^2 per day (1000 mg/m^2 BID) from Days 1-14 every 3 w... | {'Clinical Trial ID': 'NCT00319254', 'Intervention': ['INTERVENTION 1: ', ' Bosutinib', ' Four bosutinib 100 milligram (mg) capsules, equivalent to 400 mg bosutinib orally once daily for 48 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent occurred.'], 'Eligibility': ['Inclusion Crit... | 2ca24749-7c1d-4697-a1aa-8bf5d13fb8c3 |
Single | Results | NCT00513292 | In the primary trial the FEC-75 Then Paclitaxel/Trastuzumab group produced better Pathological complete response (pCR) rates than the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00513292', 'Intervention': ['INTERVENTION 1: ', ' FEC-75 Then Paclitaxel/Trastuzumab', ' Patients receive Fluorouracil, epirubicin, and cyclophosphamide (FEC) comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 cour... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1e91c023-96e8-459b-9070-02df13339617 | |
Single | Adverse Events | NCT03012477 | One patient in the primary trial experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Anemia. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT03012477', 'Intervention': ['INTERVENTION 1: ', ' Cisplatin + AZD1775', ' Treatment will consist of one cycle of cisplatin monotherapy (cisplatin 75 mg/m2 IV x1) followed by combination therapy of AZD1775 plus cisplatin starting 21 days(1 cycle) later.', ' AZD1775 will be administered 200 m... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a15b4c0c-232b-4209-bf60-35d160e41d2c | |
Single | Intervention | NCT02667626 | the primary trial is testing a web-based educational tool and the secondary trial is testing a medical device on Post-menopausal Women. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [] | {'Clinical Trial ID': 'NCT02667626', 'Intervention': ['INTERVENTION 1: ', ' SCPR Intervention', ' Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information, including resource lists of helpful websites, followed by regular reproductive heal... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 795d634a-9f9c-49a2-a4e7-ec99bd3600f2 | |
Comparison | Adverse Events | NCT01463007 | NCT00965523 | A significantly higher proportion of patients in the secondary trial suffured from infection compared to the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | {'Clinical Trial ID': 'NCT01463007', 'Intervention': ['INTERVENTION 1: ', ' Radiation', ' AccuBoost APBI- 34.0 Gy in 10fx', ' Accelerated partial breast irradiation: Accuboost APBI 34.0 Gy in 10 fractions', 'INTERVENTION 2: ', ' Extended to 5 Years of Follow Up-Rhode Island Hospital Only', ' Follow up has been ext... | {'Clinical Trial ID': 'NCT00965523', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate', ' Eribulin mesylate 1.4 mg/m^2 intravenous infusion given over 2 to 5 minutes on Day 1 and 8 every 21 days.'], 'Eligibility': ['Inclusion criteria:', ' Female patients with histologically or cytologically confirmed breast... | e2d4c56c-a68f-4751-907d-9c2355c9528b |
Comparison | Eligibility | NCT00193050 | NCT00232479 | Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial or the secondary trial. | Contradiction | [
0,
3,
11,
13
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT00193050', 'Intervention': ['INTERVENTION 1: ', ' Intervention', ' In the neoadjuvant setting, patients were administered gemcitabine (800 mg/m2 IV days 1 and 8), epirubicin (75 mg/m2 IV day 1), and docetaxel (30 mg/m2 IV days 1 and 8)repeated every 21 days for 4 cycles', ' Patients then ha... | {'Clinical Trial ID': 'NCT00232479', 'Intervention': ['INTERVENTION 1: ', ' Group 1', ' patients received dose dense herceptin, carboplatin and taxotere'], 'Eligibility': ['Inclusion Criteria:', ' HER-2 overexpressing breast cancer', ' Clinical stage 2-3B', ' Normal ejection fraction', 'Exclusion Criteria:', ' Me... | 50f1c6c5-abe6-4178-93cf-32b5a8a3e9e9 |
Comparison | Adverse Events | NCT00243503 | NCT00448279 | the primary trial and the secondary trial did not observe any of the same adverse events in their patients. | Contradiction | [
0,
1,
3
] | [
0,
2
] | {'Clinical Trial ID': 'NCT00243503', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + Sunitinib', ' Trastuzumab was administered intravenously (i.v) weekly (loading 4 mg/kg followed by weekly 2 mg/kg) or every 3 weeks (loading 8 mg/kg followed by 6 mg/kg thrice weekly). Sunitinib began with 37.5 mg by oral capsul... | {'Clinical Trial ID': 'NCT00448279', 'Intervention': ['INTERVENTION 1: ', ' Chemotherapy Alone', " Participants received chemotherapy until disease progression, unacceptable toxicity, or death; the schedule and dose at the investigator's discretion and per local prescribing guidelines and standard center practice. Al... | 9ad3444c-143d-4c28-a08a-e0c9cda44900 |
Comparison | Intervention | NCT01401959 | NCT00852930 | the primary trial designates specific interventions to its patients depending on their tumour response, patients with complete response go to cohort A and all other in cohort B, in contrast the secondary trial assigns interventions randomly. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT01401959', 'Intervention': ['INTERVENTION 1: ', ' Cohort A: Triple-negative Breast Cancer Patients', ' Patients with triple-negative breast cancer who do not have a pathological complete response following neoadjuvant therapy and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every... | {'Clinical Trial ID': 'NCT00852930', 'Intervention': ['INTERVENTION 1: ', ' Laser Therapy Alone', ' therapist administered laser treatment', ' laser: therapist administered laser', 'INTERVENTION 2: ', ' Mld Alone', ' therapist administered manual lymphatic drainage', ' manual lymphatic drainage: therapist adminis... | 43061a8b-c1b2-4b5e-b935-73733d674fb4 |
Single | Eligibility | NCT00416572 | Patients suffering from ovarian or lung cancer are excluded from the primary trial. | Entailment | [
12,
13
] | [] | {'Clinical Trial ID': 'NCT00416572', 'Intervention': ['INTERVENTION 1: ', ' Education Intervention', " Participants attended 2-hr education sessions once a month, for 4 months. The overall goal of the sessions was to provide information that would reduce participants' uncertainty about their illness/treatment, to enh... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | fc7369dc-0fc5-4823-a8eb-5ac85188fd60 | |
Comparison | Intervention | NCT03475992 | NCT03106077 | Participants in the primary trial receive different interventions depending on their pre-diagnosis, whereas all patients in the secondary trial took the same intervention. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT03475992', 'Intervention': ['INTERVENTION 1: ', ' Pre-diagnosed Breast Cancer - Biopsy Confirmed', ' Low-power microwave breast imaging system.', ' Core needle biopsy performed 14 days before the microwave breast investigation', ' Low-power microwave breast imaging system: Investigate the ... | {'Clinical Trial ID': 'NCT03106077', 'Intervention': ['INTERVENTION 1: ', ' Cohort A: Advanced Triple-Negative Breast Cancer (TNBC)', ' 6 mg/kg IMGN853 IV Q3W'], 'Eligibility': ['Inclusion Criteria:', ' Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1', ' Confirmed invasive triple-negative bre... | 25ec56f0-e472-4423-92ae-8d4840b067b5 |
Single | Intervention | NCT02286843 | the primary trial is testing a novel radiotracer called PET/CT to evaluate its use for visualization of HER2+ lesions. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT02286843', 'Intervention': ['INTERVENTION 1: ', ' HER2-targeted PET/CT', ' Pts with confirmed HER2- breast cancer will undergo HER2-targeted PET/CT. 89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. 89Zr-pertuzumab is a novel radiotracer which may... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2c9e9407-e990-41bd-a87b-9d294c78f727 | |
Single | Adverse Events | NCT00693719 | the primary trial recorded less than 5 different Adverse Events . | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00693719', 'Intervention': ['INTERVENTION 1: ', ' Etoposide/Irinotecan', ' Irinotecan hydrochloride : Irinotecan 100 mg/m2 IV days 1 and 15, 28 day/Cycle', ' Etoposide : 50 mg PO x14 days followed by 2 weeks off, 28 day/Cycle'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Diagnosis of lo... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f3cebdf7-be0c-45ad-85bd-bde827524e20 | |
Single | Adverse Events | NCT01705691 | A patient in the primary trial suffered from Kidney stones. | Entailment | [
9,
14
] | [] | {'Clinical Trial ID': 'NCT01705691', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: Paclitaxel Then AC', ' Paclitaxel 80 mg/m2 IV weekly for 12 doses followed by doxorubicin and cyclophosphamide IV every 21 days for 4 cycles', ' Paclitaxel: 80 mg/m2 IV over 60 minutes weekly for 12 weeks', ' Doxorubicin: 60 mg/m2 IV... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b5c7bfd2-d491-400c-8444-8bc424cd5dbf | |
Single | Intervention | NCT00425672 | Patients receiving intervention 1 of the primary trial undergo a 21 day treatment cycle, up to a total of 6 times, but will stop earlier if they suffer disease progression or unacceptable toxicity occurs. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [] | {'Clinical Trial ID': 'NCT00425672', 'Intervention': ['INTERVENTION 1: ', ' Arm I', ' Patients receive ONTAK IV over 1 hour on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.', ' ONTAK: Given IV', ' flow cytometry: Correlative studies', '... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 53c62057-d6ea-4639-adaf-98cb1544a394 | |
Comparison | Results | NCT01570036 | NCT00021255 | the primary trial and the secondary trial monitor the % of their patient cohorts with DFS < 6years. | Contradiction | [
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT01570036', 'Intervention': ['INTERVENTION 1: ', ' Herceptin + NeuVax Vaccine', ' Patients randomized to this arm will receive Herceptin every 3 weeks as monotherapy for 1 year; the first Herceptin infusion will be given no sooner than 3 weeks and no later than 12 weeks after completion of st... | {'Clinical Trial ID': 'NCT00021255', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T)', ' Doxorubicin 60 mg/m² IV bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus injection on Day 1 of every 3 weeks for 4 cycles followed by docetaxel 100 mg/m... | 599b37cd-f380-48ac-864d-e766a7af963e |
Single | Eligibility | NCT02222337 | Participants for the primary trial must be in pairs, a breast cancer survivor and a caregiver, both must be ethnically Hispanic. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT02222337', 'Intervention': ['INTERVENTION 1: ', ' Usual Care Survivors', ' Survivors randomized to usual care as provided by each of our 4 community-based organization partners. Usual care can include but is not limited to support groups, patient navigation, individual, couple or family ther... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c428ec76-4d22-4d2d-8c06-1675bd431d41 | |
Single | Intervention | NCT03283553 | the primary trial has two cohorts. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT03283553', 'Intervention': ['INTERVENTION 1: ', ' Multicomponent Intervention', " 1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6cbc1567-2b51-45c0-ab1b-cac0b5fc7c38 | |
Comparison | Eligibility | NCT00089479 | NCT02964234 | Agatha had her 53rd birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. Agatha is of white british origin. she is eligible for the primary trial but not the secondary trial, due to her age. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00089479', 'Intervention': ['INTERVENTION 1: ', ' AC Then T', ' Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Taxotere 100 mg/m^2; repeat every 3 weeks for 4 cycles', 'INTERVENTION 2: ', ' AC Then XT', ' Adriamycin 60 mg/m^2 iv plus Cytoxa... | {'Clinical Trial ID': 'NCT02964234', 'Intervention': ['INTERVENTION 1: ', ' Empowerment', ' Behavior: Empowerment', ' Empowerment: Three group sessions (breast cancer education; communication; volunteerism) 1.5 hours 3 times across 3 weeks', 'INTERVENTION 2: ', ' Education', ' Behavior: Education', ' Education: T... | a9d5c664-896f-4bb1-95e7-1deaa88848ef |
Comparison | Adverse Events | NCT00471276 | NCT00951665 | Gastrointestinal haemorrhage was more common in patients from cohort 1 of the primary trial than cohort 1 of the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | {'Clinical Trial ID': 'NCT00471276', 'Intervention': ['INTERVENTION 1: ', ' Sunitinib', ' Sunitinib 37.5 milligrams (mg) daily by oral capsule in continuous daily dose (CDD) schedule. Dose adjustments, if needed, included a reduction to 25mg daily or escalation to 50mg daily anytime after Week 12.'], 'Eligibility': [... | {'Clinical Trial ID': 'NCT00951665', 'Intervention': ['INTERVENTION 1: ', ' Phase Ib Regimen 1', ' Participants received T-DM1 Q3W + paclitaxel QW intravenously.', 'INTERVENTION 2: ', ' Phase Ib Regimen 2', ' Participants received T-DM1 Q3W + paclitaxel QW + pertuzumab Q3W intravenously.'], 'Eligibility': ['Inclusi... | 62b5fe62-470d-46e3-82a6-d57cd6cab452 |
Comparison | Results | NCT01106040 | NCT01441596 | the primary trial and the secondary trial are not studying patient PFS, ORR or DLTs. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT01106040', 'Intervention': ['INTERVENTION 1: ', ' Intent-To-Treat', ' Participants received a single dose of 50 μg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.'], 'Eligibility': ['Inclusion Criteria:', ' The pat... | {'Clinical Trial ID': 'NCT01441596', 'Intervention': ['INTERVENTION 1: ', ' Afatinib Mono', ' Afatinib monotherapy administered orally: starting dose 40 mg per day, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.', 'INTERVENTION 2: ', ' Afatinib+Vino', ' Afatinib 40... | de349a2d-80ee-4c34-ab9f-38eb467c77d7 |
Comparison | Intervention | NCT00446030 | NCT00975676 | the primary trial and the secondary trial have no overlap in the drugs they use for their interventions. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00446030', 'Intervention': ['INTERVENTION 1: ', ' Stratum 1: TAC + Bevacizumab', ' HER2 negative participants were administered chemotherapy with docetaxel, doxorubicin and cyclosphosphamide (TAC) + bevacizumab every 3 weeks for 6 cycles, and maintenance therapy with bevacizumab every 3 week... | {'Clinical Trial ID': 'NCT00975676', 'Intervention': ['INTERVENTION 1: ', ' Triptorelin Plus Tamoxifen', ' Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years.', 'INTERVENTION 2: ', ' Triptorelin Plus Exemestane', ' Determination of estrogen leve... | 0d37bf26-bc74-4a01-9bc9-61e2fa3051da |
Comparison | Results | NCT02425891 | NCT00593827 | the secondary trial and the primary trial both measure PFS of their patient cohorts. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02425891', 'Intervention': ['INTERVENTION 1: ', ' Placebo Plus Nab-Paclitaxel', ' Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.', 'INTERVENTION 2: ', ' Atezolizumab Plus Nab-Paclitaxel', ' Participants assigned... | {'Clinical Trial ID': 'NCT00593827', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone 16 mg/m^2', ' ixabepilone 16 mg/m^2 weekly for 3 weeks followed by 1 week rest', 'INTERVENTION 2: ', ' Ixabepilone 40 mg/m^2', ' ixabepilone 40 mg/m^2 every 3 weeks'], 'Eligibility': ['Inclusion Criteria:', ' Has MBC that is me... | 69f7a93d-7134-40ec-aff3-50acd7119d2c |
Single | Eligibility | NCT01299038 | Joe has a known history of Hepatitis. However as he is over the age of 18 is still eligible for the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT01299038', 'Intervention': ['INTERVENTION 1: ', ' Rosuvastatin 20mg', ' Rosuvastatin 20mg taken orally once a day for 4 weeks', ' rosuvastatin: Taken orally once a day for 4 weeks', 'INTERVENTION 2: ', ' Rosuvastatin 40mg', ' Rosuvastatin 40mg taken orally once a day for 4 weeks', ' rosu... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8de31b0f-7127-4c8b-b5e0-060e7a83fae5 | |
Comparison | Adverse Events | NCT01008150 | NCT00375427 | In total the secondary trial recorded only 1 more case of Mucosal inflammation than the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | {'Clinical Trial ID': 'NCT01008150', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: Paclitaxel + Trastuzumab Then A C', ' 4 cycles of paclitaxel 80 mg/m2 on Days 1, 8, and 15 of a 28-day cycle. Trastuzumab concurrently with paclitaxel weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Followin... | {'Clinical Trial ID': 'NCT00375427', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid Every 3 Months', ' Zoledronic acid given as a 15-minute (at least) i.v. infusion every three months. The dose of study drug was the same as administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 ... | 207a1d82-a61b-4b5f-bebf-0706def6729d |
Single | Adverse Events | NCT01491737 | There were 4 cases of Febrile neutropenia and heart failure in cohort 1 of the primary trial. | Contradiction | [
0,
2,
5
] | [] | {'Clinical Trial ID': 'NCT01491737', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy', ' Participants received pertuzumab at a loading dose of 840 mg followed by 420 mg along with trastuzumab at a loading dose of 8 mg/kg of body weight followed by 6 mg/kg of body weight on... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 968aeaf1-44b9-4454-8c99-e3c207037485 | |
Single | Eligibility | NCT02988986 | Patients must have AST, ALP and ALT < 1.5 ULN to participate in the primary trial. | Entailment | [
0,
20
] | [] | {'Clinical Trial ID': 'NCT02988986', 'Intervention': ['INTERVENTION 1: ', ' TAK-228 Plus Tamoxifen', ' TAK-228 will be orally administered at 30 mg weekly for 16 weeks.', ' Tamoxifen will be orally administered at 20 mg daily for 16 weeks.', ' TAK-228: MTORC1/2 inhibitor', ' Tamoxifen: Non-steroidal anti-estrogen'... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2b79f9cc-4262-4353-ad28-91cda07a9b9a | |
Single | Eligibility | NCT00723398 | Patients with diabetes insipidusare not suitable for the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00723398', 'Intervention': ['INTERVENTION 1: ', ' Group 1: Control', ' Control, no intervention', 'INTERVENTION 2: ', ' Group 2: Raloxifene 60 mg', ' Raloxifene 60 mg Orally Daily'], 'Eligibility': ['Inclusion Criteria:', ' Postmenopausal status defined as history of at least 12 months wi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d56ffd81-4007-477b-b3c3-0fdb89806931 | |
Comparison | Intervention | NCT01373671 | NCT00686127 | Lidoderm products are used in a intervention arm 1 of the secondary trial, and an FFDM product is used in arm 1 of the primary trial | Contradiction | [
0,
1,
2
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01373671', 'Intervention': ['INTERVENTION 1: ', ' FFDM and DBT', ' FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration', 'INTERVENTION 2: ', ' FFDM Only', 'FFDM exam only'], 'Eligibility': ['Inclusion Criteria:', ' All subjects enrolled into the collection study must:', ' Provide signe... | {'Clinical Trial ID': 'NCT00686127', 'Intervention': ['INTERVENTION 1: ', ' Lidocaine Patch', ' Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.): 1 patch was applied topically to the affected site(s) for 12 hours each day.', 'INTERVENTION 2: ', ' Placebo Patch', ' Placebo patch: 1 patch was applied topical... | f62e6c20-862b-4ce3-9121-0d93ff050839 |
Comparison | Results | NCT02162719 | NCT02131064 | the primary trial and the secondary trial investigate the effects of their intervention on patient tpCR. | Contradiction | [
0,
1,
2,
3
] | [
0,
1
] | {'Clinical Trial ID': 'NCT02162719', 'Intervention': ['INTERVENTION 1: ', ' Ipatasertib and Paclitaxel', ' Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, in... | {'Clinical Trial ID': 'NCT02131064', 'Intervention': ['INTERVENTION 1: ', ' TCH + P', ' Participants received pertuzumab 840 milligrams (mg) (loading dose) and 420 mg (maintenance dose) intravenous (IV) infusion, trastuzumab 8 milligrams per kilogram (mg/kg) (loading dose) and 6 mg/kg (maintenance dose) IV infusion, ... | 833eeb4b-4921-468a-947d-bacfc7816ae6 |
Comparison | Adverse Events | NCT00006110 | NCT00464646 | the secondary trial records several gastrointestinal adverse events, whereas the primary trial doesn’t record any GI adverse events. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [
0,
7,
8,
9
] | {'Clinical Trial ID': 'NCT00006110', 'Intervention': ['INTERVENTION 1: ', ' Herceptin Regimen After AC', ' Patients in the adjuvant and neoadjuvant groups after receiving [AC-TP] Chemotherapy (doxorubicin & cyclophosphamide).', 'INTERVENTION 2: ', ' Herceptin Regimen After TP', ' Patients in the adjuvant and neoadj... | {'Clinical Trial ID': 'NCT00464646', 'Intervention': ['INTERVENTION 1: ', ' Cohort A', ' Cohort A: Women with unresected locally advanced breast cancer (clinical Stage IIIA, IIIB, and IIIC)', 'INTERVENTION 2: ', ' Cohort B', ' Cohort B: Women with resected pN2 or pN3 (pathologic Stage III) breast cancer'], 'Eligibili... | 6dea5ffa-066d-45bf-b7e5-df3ae5bca0b6 |
Comparison | Intervention | NCT01129622 | NCT01156987 | the secondary trial and the primary trial both used MRI for their interventions. | Entailment | [
0,
1,
2
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT01129622', 'Intervention': ['INTERVENTION 1: ', ' Letrozole, Breast Enhancement, Safety', ' Single arm of healthy postmenopausal women to have two breast MRI (baseline and post-treatment). Letrozole of 12.5 mg/day is given for three successive days just prior to the second MRI.'], 'Eligibili... | {'Clinical Trial ID': 'NCT01156987', 'Intervention': ['INTERVENTION 1: ', ' Healthy Volunteers', ' Healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection, and SWIFT acquisition.', ' Magnetic resonance imaging: Patients and healthy volunteers will be... | c317750d-6ef7-494d-8040-2c7fa3d777fb |
Single | Adverse Events | NCT00567190 | There was exactly the same proportion of anemic patinets in both cohorts of the primary trial. | Contradiction | [
0,
2,
12,
14
] | [] | {'Clinical Trial ID': 'NCT00567190', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab + Trastuzumab + Docetaxel', ' Participants randomized to this arm received pertuzumab 420 milligrams (mg) intravenously (IV) once every 3 weeks (q3w) and trastuzumab 6 milligrams per kilogram (mg/kg) IV q3w, plus docetaxel 75 milli... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 87eca8d2-72fe-4285-9884-6d2ec7bae6df | |
Comparison | Intervention | NCT01000662 | NCT02413008 | the secondary trial is testing a Gel which is applied inside the vagina, and the primary trial is testing an intervention which requires daily radiation of the breast(s). | Entailment | [
0,
1,
2,
3,
4
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01000662', 'Intervention': ['INTERVENTION 1: ', ' ARM 1 Daily Boost', ' Radiation Therapy', ' Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy, Monday to Friday for 3 weeks, to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose... | {'Clinical Trial ID': 'NCT02413008', 'Intervention': ['INTERVENTION 1: ', ' 0.005% Estriol Vaginal Gel', ' Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly admini... | 7a87c605-fc41-4d0a-9291-85e88f6eb510 |
Comparison | Results | NCT01964924 | NCT00524303 | the primary trial and the secondary trial both report results on pathologic evidence of invasive disease withing their patient cohorts after their interventions, using different outcome measurements. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT01964924', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Trametinib, Akt Inhibitor GSK2141795)', ' PART 1: Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progress... | {'Clinical Trial ID': 'NCT00524303', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' Participants received trastuzumab alone (a loading dose of 4 milligrams [mg]/kilogram [kg] on Day 1, followed by a dose of 2 mg/kg on Day 1 of Week 2 and weekly thereafter). Participants were treated with trastuzumab in a 2-we... | fbb853c9-bed4-4cde-a283-2d91b23d35bf |
Single | Eligibility | NCT00482391 | Patients with a QT interval longer than half a second are excluded from the primary trial. | Entailment | [
29
] | [] | {'Clinical Trial ID': 'NCT00482391', 'Intervention': ['INTERVENTION 1: ', ' AC, PACLITAXEL , TRASTUZUMAB & LAPATINIB', " The regimen consists of AC (doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 4 with pegfilgrastim, followed by weekly paclitaxel (80 mg/m2) x 12 + trastuzumab (H) + lapatinib (L). Pegf... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c3cc3621-a8ce-4f0d-a150-7e627f36e7c5 | |
Single | Intervention | NCT01441596 | Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib monotherapy, up to 160% of the starting dose. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT01441596', 'Intervention': ['INTERVENTION 1: ', ' Afatinib Mono', ' Afatinib monotherapy administered orally: starting dose 40 mg per day, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.', 'INTERVENTION 2: ', ' Afatinib+Vino', ' Afatinib 40... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 84aa97cf-efce-484e-825e-5af509e5988f | |
Comparison | Intervention | NCT03076190 | NCT03196635 | Molecular Breast Imaging is not applied in either the primary trial or the secondary trial interventions, however all participants taking part in these studies will need to receive stem cell transplants. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT03076190', 'Intervention': ['INTERVENTION 1: ', ' Active Control Group', ' Health Education Active Control Group', 'INTERVENTION 2: ', ' My Surgical Success Treatment Group', ' My Surgical Success Intervention Group'], 'Eligibility': ['Inclusion Criteria:', ' Age 18+', ' Scheduled for br... | {'Clinical Trial ID': 'NCT03196635', 'Intervention': ['INTERVENTION 1: ', ' All Study Participants, PA Compression Image Sets', ' All image sets (30 patient-assisted compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers.', 'INTERVENTION 2: ', ' All Study Partic... | a40e172a-8839-499d-896d-be71a7ca4905 |
Single | Intervention | NCT02202252 | The difference between cohort 1 and 2 of the primary trial is assesment by ultrasonography and the insertion of an additional negative pressure drain for patients in cohort 2. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
5,
10,
5
] | [] | {'Clinical Trial ID': 'NCT02202252', 'Intervention': ['INTERVENTION 1: ', ' Single Drain', ' Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla in the single drain group.', ' Ultrasonography after removal of the drains: One day after removal of the dr... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9e972e33-9ecd-4a8b-8337-7bee209f790b | |
Comparison | Intervention | NCT01943916 | NCT01653964 | All subjects in the primary trial and the secondary trial will be adminstered 4 mCi Tc-99m sestamibi and undergo Molecular breast imaging. | Contradiction | [
0,
1,
2
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01943916', 'Intervention': ['INTERVENTION 1: ', ' Overall Population', ' Each subject served as her own control, with imaging of each mass by both the test and control modalities. Specificity difference is a single measure for the overall ITD population.'], 'Eligibility': ['Inclusion Criteri... | {'Clinical Trial ID': 'NCT01653964', 'Intervention': ['INTERVENTION 1: ', ' Molecular Breast Imaging', ' Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi.'], 'Eligibility': ['Inclusion Criteria:', ' Subgroup 1, Patients with breast lesions:', ' -At ... | f29768ba-5d79-4528-839f-933ab13faaa1 |
Comparison | Adverse Events | NCT00392392 | NCT00503906 | the primary trial records two different types of pain in its adverse events, in the abdomen and chest area, the secondary trial does not record any types of pain in its participants. | Entailment | [
0,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | {'Clinical Trial ID': 'NCT00392392', 'Intervention': ['INTERVENTION 1: ', ' Nab-Paclitaxel/Bevacizumab/Trastuzumab', ' Patients received treatment with nab-paclitaxel (100 mg/m2 IV days 1, 8, 15) and carboplatin (AUC 6 IV day 1) every 28 days for 6 cycles. Trastuzumab (4 mg/kg loading dose, followed by 2 mg/kg) and b... | {'Clinical Trial ID': 'NCT00503906', 'Intervention': ['INTERVENTION 1: ', ' Abraxane, Avastin and Gemcitabine', ' Each treatment cycle is 28 days. Participants will be treated until disease progression:', ' Gemcitabine: 1500 mg/m2 body surface area (BSA) intravenously (IV) over 30 minutes (+/- 5 minutes) on days 1 a... | 343e0a32-aebe-4bbb-97c0-b2c597c36802 |
Single | Intervention | NCT00558103 | All participants in the primary trial are administered with Lapatinib 1500 mg PO QD and Pazopanib 800 mg. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00558103', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo', ' Participants received oral lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with placebo (matching to pazopanib; 2 tablets) once daily (QD).', 'INTERVENTION 2: ', ' Cohort... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4d51608c-b0d8-4019-9b9a-34cf1c3d5087 | |
Comparison | Intervention | NCT00331552 | NCT01306942 | trastuzumab was used for the interventions in the primary trial and the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00331552', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Cyclophosphamide, Doxil, Trastuzumab', ' Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease p... | {'Clinical Trial ID': 'NCT01306942', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2', ' Cohort 1: Eligible patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg... | 7bb88699-1536-4fdc-9cb2-c5ef350d559b |
Comparison | Adverse Events | NCT02139358 | NCT02574455 | There was one case of hemorrhaging in the primary trial, and no recorded cases in the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | {'Clinical Trial ID': 'NCT02139358', 'Intervention': ['INTERVENTION 1: ', ' Dose Escalation / Phase II Treatment', ' Single arm, non-randomized, open label phase I/II multisite Simon two stage minimax trial. Gemcitabine plus trastuzumab and pertuzumab.'], 'Eligibility': ['Inclusion Criteria:', ' Adult males or femal... | {'Clinical Trial ID': 'NCT02574455', 'Intervention': ['INTERVENTION 1: ', ' Sacituzumab Govitecan', ' Participants received sacituzumab govitecan 10 mg/kg of body weight, administered as a slow IV infusion either by gravity or with an infusion pump on Days 1 and 8 of a 21-day treatment cycle for up to 29.6 months. In... | c86ef61b-7565-465a-82ba-25e7ac050ccc |
Comparison | Adverse Events | NCT02019277 | NCT00863655 | the primary trial and the secondary trial recorded three of the same types of adverse events | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT02019277', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab, Pertuzumab, and Taxane', " Participants received first-line therapy with pertuzumab administered via IV infusion on Day 1 of first treatment cycle (1 cycle = 21 days) at a loading dose of 840 mg, followed by 420 mg on Day 1 of ea... | {'Clinical Trial ID': 'NCT00863655', 'Intervention': ['INTERVENTION 1: ', ' Everolimus + Exemestane', ' Everolimus 10 mg daily in combination with exemestane 25 mg daily', 'INTERVENTION 2: ', ' Placebo + Exemestane', ' Placebo of everolimus in combination with exemestane 25 mg daily'], 'Eligibility': ['Inclusion Cr... | 58dec898-e0af-41c1-96f9-7163d3e3e855 |
Single | Adverse Events | NCT02291913 | One patient in the primary trial suffered from an inflammation of the liver. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT02291913', 'Intervention': ['INTERVENTION 1: ', ' Everolimus', ' Everolimus will be administered at a dose of 10 mg PO daily combined with any one of the following anti-estrogen therapies on which the patient most recently progressed (tamoxifen, fulvestrant, anastrozole, letrozole, exemestan... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5cf74526-9f91-498d-a13a-6393dcd45b7b | |
Single | Results | NCT00191269 | the primary trial did not use PFS to evaluate the performance of its interventions. | Entailment | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT00191269', 'Intervention': ['INTERVENTION 1: ', ' Dose Level 1', ' Gemcitabine at 1000 mg/m2 administered intravenously over 30 to 60 minutes on Days 1 and 8 in each 3-week (21-day) cycle of study therapy.', 'INTERVENTION 2: ', ' Dose Level 2', ' Gemcitabine at 1250 mg/m2 administered intr... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 154caa20-3be1-4cee-a838-2d90b44566c4 | |
Single | Adverse Events | NCT02001974 | No cases of Oesophageal adenocarcinoma were recorded in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT02001974', 'Intervention': ['INTERVENTION 1: ', ' Group 1', ' Paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15 of 28-day cycle) + reparixin oral 400 mg three times daily (t.i.d.) three weeks on one week off (three to six patients)', 'INTERVENTION 2: ', ' Group 2', ' Paclitaxel 80 mg/m2 i.v. (Da... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c40d8532-4e66-4eef-9644-91f20a02066d | |
Comparison | Intervention | NCT01289353 | NCT00429182 | the primary trial and the secondary trial both administer bi-weekly oral Carboplatin to their test groups. | Contradiction | [
0,
3
] | [
0,
2,
3
] | {'Clinical Trial ID': 'NCT01289353', 'Intervention': ['INTERVENTION 1: ', ' ChemoRT', ' Concurrent Carboplatin and Radiotherapy', ' Carboplatin: IV, weekly for 6 weeks, AUC of 2.0', ' 3D-RT or IMRT: From week 2 to week 4 in the 6-week Carboplatin treatment: Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 tim... | {'Clinical Trial ID': 'NCT00429182', 'Intervention': ['INTERVENTION 1: ', ' High-dose Chemotherapy', ' Carboplatin + Cyclophosphamide + Thiotepa', ' Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.', ' Thiotepa : 120 mg/m^2 by vein days -6... | 3d450be5-4587-48e5-ae2e-745623606631 |
Single | Results | NCT00943670 | The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle, post T-DM1 intravenous (IV) infusion. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [] | {'Clinical Trial ID': 'NCT00943670', 'Intervention': ['INTERVENTION 1: ', ' T-DM1', ' Trastuzumab emtansine (T-DM1) was administered to participants by intravenous (IV) infusion on Day 1 of every 3 week cycle at a dose of 3.6 mg/kg.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically documented, locally advan... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | fa28753a-aa3b-4642-9fd4-a2414fd8a472 | |
Comparison | Intervention | NCT01000662 | NCT02413008 | the secondary trial is testing a Gel which is applied to the breast, whereas the primary trial is testing an intervention which requires daily radiation of the breast. | Contradiction | [
0,
1,
2,
3,
4
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01000662', 'Intervention': ['INTERVENTION 1: ', ' ARM 1 Daily Boost', ' Radiation Therapy', ' Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy, Monday to Friday for 3 weeks, to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose... | {'Clinical Trial ID': 'NCT02413008', 'Intervention': ['INTERVENTION 1: ', ' 0.005% Estriol Vaginal Gel', ' Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly admini... | 5e700303-cd26-4024-a260-62f6a1c297ed |
Comparison | Adverse Events | NCT00371345 | NCT00475670 | There is no overlap between adverse events obeserved in the primary trial and the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | {'Clinical Trial ID': 'NCT00371345', 'Intervention': ['INTERVENTION 1: ', ' Her2/Neu-amplified Tumor, 70 mg Twice Daily (BID) Dasatinib', ' Participants with a Human epidermal growth factor (Her2/neu)-amplified tumor type (defined as 3+ by immunohistochemistry [IHC] or positive by fluorescent or chromogenic in situ h... | {'Clinical Trial ID': 'NCT00475670', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Monotherapy', ' Participants received either an initial loading dose of trastuzumab 4 mg/kg, IV, on Day 1, followed by 2 mg/kg, IV, once per week, or an initial loading dose of 8 mg/kg IV on Day 1, followed by 6 mg/kg IV once ever... | 4c4c191c-de68-44c8-a23c-2455acc43d46 |
Comparison | Intervention | NCT01818063 | NCT00559507 | In the primary trial and the secondary trial the only drugs administered orally are saracatinib and Veliparib. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01818063', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 (Paclitaxel, Carboplatin)', ' Patients receive paclitaxel IV and carboplatin IV on day 1 (course 1 only) or day 2 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxici... | {'Clinical Trial ID': 'NCT00559507', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Enzyme Inhibitor Therapy)', ' Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically... | e5a4cb11-2a00-4144-93ba-f5462d7efbf0 |
Comparison | Intervention | NCT01720602 | NCT00082810 | the primary trial participants receive more anastrozole, letrozole and exemestane than patients in the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01720602', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Vorinostat, AI Therapy)', ' Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat e... | {'Clinical Trial ID': 'NCT00082810', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant 250 mg + Tipifarnib 300 mg', ' Patients receive fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable to... | 03d72e5f-b921-4aeb-802c-4dc4ee1a7e4c |
Single | Results | NCT01945775 | The shortest PFS in the Talazoparib group of the primary trial was over a month longer than the study duration. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01945775', 'Intervention': ['INTERVENTION 1: ', ' Talazoparib', " Participants received talazoparib 1 mg, orally, once daily until radiographic disease progression as determined by the central IRF, unacceptable toxicity, consent withdrawal, physician's decision to terminate treatment, or spo... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 27a4d1a8-185b-4483-85ce-0fbb3d323b99 | |
Single | Results | NCT01743560 | By week 48 of the primary trial none of the patients had Complete Response, 7 had partial response and 15 had progressive disease. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | [] | {'Clinical Trial ID': 'NCT01743560', 'Intervention': ['INTERVENTION 1: ', ' Everolimus and Exemestane', ' Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive everolimus at a dose of 10mg daily p.o. and exemestane 25mg daily p.o.'], 'Eligibility': [... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ff797dd4-0b4d-42fc-808d-27c439563ce2 | |
Single | Eligibility | NCT00494481 | Paula recently had fell down a flight of stairs and fractured her hip, she is excluded from the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00494481', 'Intervention': ['INTERVENTION 1: ', ' Vandetanib Plus Docetaxel', ' vandetanib 100 mg plus docetaxel', 'INTERVENTION 2: ', ' Placebo Plus Docetaxel', ' placebo plus docetaxel'], 'Eligibility': ['Inclusion Criteria:', ' Females with histological/cytological confirmation of brea... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9f666667-0fde-4d79-b53c-33c0ffbbed90 | |
Single | Eligibility | NCT00494481 | Paula recently had a heart attack, she is excluded from the primary trial. | Entailment | [
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00494481', 'Intervention': ['INTERVENTION 1: ', ' Vandetanib Plus Docetaxel', ' vandetanib 100 mg plus docetaxel', 'INTERVENTION 2: ', ' Placebo Plus Docetaxel', ' placebo plus docetaxel'], 'Eligibility': ['Inclusion Criteria:', ' Females with histological/cytological confirmation of brea... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 47084742-d031-4e59-865c-d8687282c782 | |
Single | Adverse Events | NCT00454805 | In the primary trial there were no cases of subendocardial myocardial infarction in cohort 1 or 2. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [] | {'Clinical Trial ID': 'NCT00454805', 'Intervention': ['INTERVENTION 1: ', ' Cediranib 45 mg', ' Cediranib 45 mg+Fulvestrant 250 mg', ' Patients randomised to the investigational arm (fulvestrant + cediranib) received treatment according to the following schedule:', ' Day 1: fulvestrant 500 mg im', ' Day 15: fulves... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ae583ea3-36a5-472c-acda-825cd7d513b6 | |
Single | Adverse Events | NCT00206427 | A patient in the primary trial had a vaginal fungal infection. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT00206427', 'Intervention': ['INTERVENTION 1: ', ' GW572016 1500mg', ' patients received GW572016 1500mg daily'], 'Eligibility': ['Inclusion Criteria:', ' All patients must be female.', ' Signed informed consent.', ' Locally advanced breast cancers or primary breast cancers with concomitan... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a18c447b-de08-48ef-8e65-0ecaa775c2b0 | |
Single | Eligibility | NCT00050167 | Patients with metastasis in four or more axillary lymph nodes are eligible for the primary trial. | Entailment | [
0,
6
] | [] | {'Clinical Trial ID': 'NCT00050167', 'Intervention': ['INTERVENTION 1: ', ' Weekly Paclitaxel (WP)', ' Weekly Paclitaxel for 12 weeks followed by Fluorouracil + Epirubicin + Cyclophosphamide (FEC) every 3 weeks for 4 cycles', 'INTERVENTION 2: ', ' Docetaxel and Capecitabine (DX)', ' Docetaxel + Capecitabine days 1-... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 18b900fb-b071-43df-b37d-c68a89ef78c0 | |
Single | Eligibility | NCT00932373 | Patients with Grade III peripheral neuropathy or above are eliminated from participation in the primary trial. | Entailment | [
10,
16
] | [] | {'Clinical Trial ID': 'NCT00932373', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab-MCC-DM1 0.3 mg/kg Every 3 Weeks', ' Trastuzumab-MCC-DM1 0.3 mg/kg administered intravenously (IV) once every 3 weeks', 'INTERVENTION 2: ', ' Trastuzumab-MCC-DM1 0.6 mg/kg Every 3 Weeks', ' Trastuzumab-MCC-DM1 0.6 mg/kg administe... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ebdf2841-b5e0-431a-8dc7-e100c5d27ccf | |
Single | Adverse Events | NCT00670982 | Acute coronary syndrome was the most prevalent adverse event in the primary trial, other than Thrombocytopenia . | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [] | {'Clinical Trial ID': 'NCT00670982', 'Intervention': ['INTERVENTION 1: ', ' First Line Treatment', ' Patients with no prior therapy for metastatic breast cancer will receive bevacizumab intravenously every 2 weeks and vinorelbine intravenously once per week, and trastuzumab intravenously once per week', 'INTERVENTION... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d56745c3-ba0b-4b42-b3cf-ac060f658d83 | |
Single | Adverse Events | NCT01446159 | the primary trial only had a total of 6 patients in across both its cohorts. | Entailment | [
0,
1,
13,
14
] | [] | {'Clinical Trial ID': 'NCT01446159', 'Intervention': ['INTERVENTION 1: ', ' MEDI-573 10 mg/kg + Aromatase Inhibitor (AI)', " Participants enrolled in Phase 1b of the study and received intravenous infusion of MEDI-573 10 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0ef77b5d-684a-4a87-bf61-8d4bc9975b7f | |
Single | Results | NCT00375505 | In the primary trial patients in control group had a Z-score of 0.037, higher than the test group score. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00375505', 'Intervention': ['INTERVENTION 1: ', ' Placebo', ' Placebo as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).', 'INTERVENTION 2: ', ' Zometa', ' Zoledronic Acid 4mg as a 15-minute infusion every 3 months for a treatment period of 2... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 03c7f31f-788c-4edb-a885-b6cb0fca05da | |
Single | Results | NCT01997333 | The minimum Progression Free Survival for patients in cohort 1 the primary trial was 1.6 months. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01997333', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine', ' Capecitabine administered on Days 1 through 14 of each 21 day cycle until disease progression, discontinuation due to toxicity, withdrawal of consent, or end of study.', 'INTERVENTION 2: ', ' CDX-011', ' CDX-011 administere... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e43c01e9-20a2-4435-a32b-224d5f460d7c | |
Comparison | Results | NCT00369655 | NCT00091832 | One patient in the primary trial had a Confirmed tumor partial response, No patients in the secondary trial were evaluated for tumor response. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT00369655', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Ziv-afibercept)', ' Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically or cyt... | {'Clinical Trial ID': 'NCT00091832', 'Intervention': ['INTERVENTION 1: ', ' Bisphosphonate IV Q4W', ' Open label bisphosphonate every 4 weeks (Q4W) by intravenous infusion', 'INTERVENTION 2: ', ' Denosumab 30 mg Q4W', ' Denosumab 30 mg by subcutaneous injection every 4 weeks (Q4W)'], 'Eligibility': ['Inclusion Crit... | c55f34ab-b883-465e-89dc-75bbeb8afa77 |
Comparison | Intervention | NCT01925170 | NCT00324259 | Participant in cohort 1 of the primary trial undergo a Mammography, whereas patients in cohort 1 of the secondary trial receive 6 mg Estradiol, and no Mammography. | Entailment | [
0,
1,
2
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01925170', 'Intervention': ['INTERVENTION 1: ', ' Mammography Only', ' For this reporting arm, the interpretation and analysis was done with mammography only.', 'INTERVENTION 2: ', ' Mammography With Adjunct MBI', ' For this reporting arm, the interpretation and analysis was done with both... | {'Clinical Trial ID': 'NCT00324259', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 (6 mg Estradiol)', ' 6 mg of estradiol daily (2 mg tid).', 'INTERVENTION 2: ', ' Arm 2 (30 mg Estradiol)', ' 30 mg of estradiol. (10 mg tid)'], 'Eligibility': ['Inclusion Criteria:', ' Postmenopausal women with advanced hormone recep... | 0ee36ceb-5790-440e-b6ad-10a0b7a23f43 |
Comparison | Eligibility | NCT02419807 | NCT00777101 | Patients with HER2 + breast cancer stage 1-4 are eligible for both the primary trial and the secondary trial. | Contradiction | [
0,
1
] | [
0,
1
] | {'Clinical Trial ID': 'NCT02419807', 'Intervention': ['INTERVENTION 1: ', ' Diagnostic (Indocyanine Green, 99mTc-labeled Radiotracer)', ' Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyani... | {'Clinical Trial ID': 'NCT00777101', 'Intervention': ['INTERVENTION 1: ', ' Neratinib', ' Neratinib', ' Neratinib: Tablets, 240mg once per day until disease progression or unacceptable toxicity', 'INTERVENTION 2: ', ' Lapatinib+Capecitabine', ' Lapatinib plus Capecitabine', ' Lapatinib: Tablets 1250mg once per da... | 2535da13-e0f7-44df-aa02-89765d8d51cb |
Single | Results | NCT00548184 | The majority of breast cancer patients in the primary trial treated with Lapatinib + Trastuzumab experienced at least Near Complete Pathologic Response, or better, after 12 weeks. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00548184', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib + Trastuzumab', ' All study participants received lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week'], 'Eligibility': ['Inclusion Criteria:', ' All patients must be female.', ' Signed informed con... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 94fc6e05-8a73-43d9-a48c-531d36dfbbcd | |
Single | Intervention | NCT01306942 | Participants of cohort 1 in the primary trial received more Dasatinib than those in cohort 2. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT01306942', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2', ' Cohort 1: Eligible patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0057172f-d019-401b-a516-993a7b46a67b | |
Comparison | Eligibility | NCT03096847 | NCT01840163 | Female Patients recently prescribed Rapamycin are not eligible for the primary trial, but may be eligible for the secondary trial as long as they have a stage 1 to 2 Ductal carcinoma in situ and can speak english. | Entailment | [
9,
10
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT03096847', 'Intervention': ['INTERVENTION 1: ', ' Ribociclib + Letrozole Cohort A', ' postmenopausal women, or men; naïve.', ' All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.', 'INTERVENTION 2: ', ' Ribociclib + Letrozole Cohort B1', ' premenopausal women ... | {'Clinical Trial ID': 'NCT01840163', 'Intervention': ['INTERVENTION 1: ', ' CanSORT Online Tool (Intervention)', ' Comprehensive (interactive) version of decision tool', ' CanSORT Online Tool', 'INTERVENTION 2: ', ' Static Version of CanSORT Tool (Control)', ' Static version (non-interactive) version of CanSORT de... | bb23e8b8-c7d6-4e58-80a2-0555db5645e9 |
Single | Intervention | NCT00545077 | Only cohort 2 of the primary trial receive Bevacizumab, but both cohorts undergo Endocrine Therapy . | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT00545077', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Endocrine Therapy (ET)', ' Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. T... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c4588d2c-b0d4-428d-a958-29787b9d4ec5 | |
Single | Eligibility | NCT00364611 | Patients with clinically significant grade 3 PVD are eligible for the primary trial. | Contradiction | [
18
] | [] | {'Clinical Trial ID': 'NCT00364611', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel and Bevacizumab', ' Stratum 1: HER2 Negative participants with metastatic breast cancer treated with DB (docetaxel and bevacizumab) intravenously (IV) every 3 weeks (q3w) until treatment discontinuation criteria (unacceptable toxici... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ee1f81d1-7e99-44dc-bb6a-ed002a78c9f6 | |
Comparison | Intervention | NCT02504424 | NCT03708393 | the primary trial and the secondary trial both require the patients to activate the interventions by remote control. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT02504424', 'Intervention': ['INTERVENTION 1: ', ' AeroForm Tissue Expander', ' AeroForm Tissue Expansion inflation with carbon dioxide by remote control', ' AeroForm Tissue Expander: The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by rem... | {'Clinical Trial ID': 'NCT03708393', 'Intervention': ['INTERVENTION 1: ', ' IUS Alone', 'IUS alone imaging', 'INTERVENTION 2: ', ' Imagio (IUS+OA)', 'IUS+OA imaging'], 'Eligibility': ['Inclusion Criteria:', ' - Female subjects participating in the PIONEER-0 Study of the Imagio Breast Imaging System with known clinic... | 00466f98-52b8-41f3-9bf1-2edaad950be9 |
Comparison | Adverse Events | NCT02445586 | NCT02115984 | More than half of patients in the primary trial experienced adverse events, and 100% of patients in the secondary trial did not experience an adverse event. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | {'Clinical Trial ID': 'NCT02445586', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab in Combination With Trastuzumab and Docetaxel', ' Participants will receive pertuzumab in combination with trastuzumab and docetaxel every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent or death, wh... | {'Clinical Trial ID': 'NCT02115984', 'Intervention': ['INTERVENTION 1: ', ' Chemotherapy & Panagen', ' Chemotherapy: Chemotherapy course includes 500 mg/m2 cyclophosphan, 50 mg/m2 doxorubicin, and 500 mg/m2 fluorouracil administered intravenously in one day.', ' Panagen 5 mg tablet by mouth every 2-3 h (six times a ... | 50a524ae-2135-45f7-ae9b-515fd4e2e404 |
Single | Eligibility | NCT01688609 | Patients must have histologically or cytologically confirmed ERBB2+ invasive breast cancer, with Primary tumor > 2 cm in diameter to participate in the primary trial. | Entailment | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT01688609', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Lapatinib, Trastuzumab, Paclitaxel, Surgery)', ' Drug exposure: Patients receive lapatinib ditosylate PO QD and trastuzumab IV over 30-90 minutes once weekly for 6 weeks in the absence of disease progression or unacceptable toxicit... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b2062e01-0ea6-4ee8-94a1-b59dc40901d3 | |
Single | Intervention | NCT00826267 | Cohort 1 and 2 of the primary trial receive different quantities of different drugs. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00826267', 'Intervention': ['INTERVENTION 1: ', ' Afatinib 50 mg', ' Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day 21 of each treatment course. 2 treatment courses were to be given in the trial.', 'INTERVENTION 2: ', ' Lapatinib 1500 mg', ' Patients... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4dbce51b-1cfc-4d5f-82bb-ce9319ace3af | |
Single | Results | NCT02447328 | In the primary trial 11 patients had serious adverse events, no patients had serious Adverse Drug Reactions, and over half of patients passed away from Unexpected adverse events. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [] | {'Clinical Trial ID': 'NCT02447328', 'Intervention': ['INTERVENTION 1: ', ' Single Arm', ' fulvestrant (Faslodex®)'], 'Eligibility': ['Inclusion Criteria:', ' Post menopausal status women', ' Outpatient or inpatient with locally advanced or metastatic breast cancer who have failed with prior anti-estrogen therapy.'... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 43a9cc96-4020-459c-8fa4-4bbde7173f7a | |
Single | Eligibility | NCT03045653 | Sharone had a hip replacement 3 weeks prior, she is not elgible for the primary trial. | Entailment | [
4,
6
] | [] | {'Clinical Trial ID': 'NCT03045653', 'Intervention': ['INTERVENTION 1: ', ' Treatment Arm', ' receiving a treatment of tamoxifen 100 mg/d'], 'Eligibility': ['Inclusion Criteria:', ' - Female 18 years, 70 years. ECOG 0-1 with no deterioration over previous 2 weeks Minimum life expectancy 3 months Histological confir... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ff319fa6-89b6-4f1a-871d-456edb91b69b | |
Single | Adverse Events | NCT00274456 | There are a total of 14 cases of neutropenia related adverse events in the primary trial across both cohorts. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT00274456', 'Intervention': ['INTERVENTION 1: ', ' ABI-007 300 mg/m^2 q3w', ' ABI-007 300 mg/m^2 administered once every third week (q3w).', 'INTERVENTION 2: ', ' ABI-007 100 mg/m^2 Weekly', ' ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest'], 'Eligibility': ['Inclusio... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a321acf0-2296-4588-bf96-85b22bf1420f | |
Single | Eligibility | NCT02027376 | A patient was treated with Pertuzumab for 6 months, and this treatment was discontinued 2 months prior to study entry and the patient has fully recovered from the entailing side effects, hence this patient is eligible for the primary trial. | Entailment | [
10,
25
] | [] | {'Clinical Trial ID': 'NCT02027376', 'Intervention': ['INTERVENTION 1: ', ' LDE225 (Sonidegib) 400mg in Combination With Docetaxel', ' Cohort 1: Eligible patients were included and treated with docetaxel intravenously (75mg/m2) in every 3 weeks cycles and LDE225 400mg was administered orally QD. Treatment was repeate... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b841dfd8-4676-4d3c-a57d-6ba1055b8597 | |
Single | Results | NCT01042535 | The Maximum Tolerated Dose (MTD) of of 1-Pemetrexed-d-tryptophan (indoximod) observed in the primary trial was 800 mg. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT01042535', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Vaccine Therapy, 1-methyl-d-tryptophan)', ' Participants receive adenovirus-p53 transduced dendritic cell (Ad.p53-DC) vaccine ID in weeks 1, 3, 5, and 10, and then every 3 weeks for 6 total doses. Participants also receive 1-methyl... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1dd4acd1-657c-40c0-b5ab-9c7adbe4ebf4 | |
Single | Intervention | NCT01209195 | Lower doses of MM-121 are utilised in cohort1 of the primary trial than in cohort 2, Paclitaxel doses are the same for both cohorts. | Entailment | [
0,
1,
2,
3,
4,
5,
6
] | [] | {'Clinical Trial ID': 'NCT01209195', 'Intervention': ['INTERVENTION 1: ', ' Part 1: Dose Escalation: Cohort 1', ' MM-121 - 20 mg/kg loading dose followed by 12 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV', 'INTERVENTION 2: ', ' Part 1: Dose Escalation: Cohort 2', ' MM-121 - 40 mg/kg loading dose followed by 20 m... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 48d40c7e-3514-43c3-a31a-7b391727f012 | |
Single | Eligibility | NCT01305941 | Patients must present IHC 3+ or FISH amplified results to participate in the primary trial, meaning their cancer is Histologically-confirmed as being HER2-positive. | Entailment | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT01305941', 'Intervention': ['INTERVENTION 1: ', ' Everolimus +Vinorelbine + Trastuzumab', ' daily everolimus plus weekly (Days 1, 8, and 15) vinorelbine and trastuzumab', ' Everolimus: everolimus 5 mg PO daily as two 2.5-mg tablets', ' Vinorelbine: vinorelbine 25 mg/m2 will be administered... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | dd98fca1-27a7-41c2-ba0c-3ff90aceab54 | |
Single | Adverse Events | NCT01989676 | the primary trial only records GI adverse events. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT01989676', 'Intervention': ['INTERVENTION 1: ', ' PF-05280014', ' Participants with human epidermal growth factor receptor 2 (HER2)-positive breast cancer received PF-05280014 on Days 1, 8, 15 and 22 of each 28-day cycle followed by paclitaxel on Days 1, 8 and 15 of each 28-day cycle both as... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b975dc12-757e-4ef5-af33-83dfce12e6cc | |
Comparison | Eligibility | NCT02658734 | NCT02073487 | Female Patients with LVEF > 50%, who have previously undergone treatment with trastuzumab emtansine or lapatinib are still eligible for the secondary trial but are excluded from the primary trial. | Entailment | [
8,
9,
10
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36
] | {'Clinical Trial ID': 'NCT02658734', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine', ' 3.6 mg/kg of trastuzumab emtansine was administered to participants intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle and was repeated every 3 weeks.'], 'Eligibility': ['Inclusion Criteria:', ' Prospect... | {'Clinical Trial ID': 'NCT02073487', 'Intervention': ['INTERVENTION 1: ', ' T-DM1 + Lapatinib + Abraxane', ' T-DM1 intravenously (IV) every three weeks plus L orally once daily for 6 weeks followed by abraxane IV weekly for 12 weeks.', ' T-DM1: antibody-drug conjugate of trastuzumab and emtansine', ' Lapatinib: Dua... | 2c4254c9-9c40-492f-aa45-2a9ab47579b3 |
Comparison | Intervention | NCT01575522 | NCT00181363 | the primary trial and the secondary trial are testing completely different modalities of interventions. | Entailment | [
0,
1,
2,
3,
4
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01575522', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Tivantinib)', ' Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection at baseline and periodically dur... | {'Clinical Trial ID': 'NCT00181363', 'Intervention': ['INTERVENTION 1: ', ' Prone', 'Prone position', 'INTERVENTION 2: ', ' Supine', 'Supine position'], 'Eligibility': ['Inclusion Criteria:', ' Patients should have had breast-conserving surgery for breast cancer or DCIS (Ductal Carcinoma in Situ)', ' No indication ... | e140b055-b7fc-4802-a79b-9dfe7d136876 |
Single | Results | NCT02581839 | At least 8 participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) >= 3 months. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT02581839', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate', ' The recommended starting dose of eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. An MRI will be completed at week 1, week 12 and every 12 weeks after cycle... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0a6418c8-63a6-4900-bfc9-1659acbe1ad7 | |
Comparison | Adverse Events | NCT00789581 | NCT02445586 | the secondary trial reported more cases of Haematemesis, but the primary trial had more cases of Sinus tachycardia. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | {'Clinical Trial ID': 'NCT00789581', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone', ' Doxorubicin and cyclophosphamide (AC) given every 3 weeks for 4 cycles, followed by ixabepilone every 3 weeks for 4 cycles.', ' Doxorubicin: 60 mg/m2', ' Cyclophosphamide: 600 mg/m2', ' Ixabepilone (Ixempra): 40 mg/m2', 'IN... | {'Clinical Trial ID': 'NCT02445586', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab in Combination With Trastuzumab and Docetaxel', ' Participants will receive pertuzumab in combination with trastuzumab and docetaxel every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent or death, wh... | 2db9e0c7-d94b-47d2-a61f-55a0896d714e |
Single | Adverse Events | NCT01644890 | Throughout the primary trial, one patient in cohort 1 developed issues with their vision. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT01644890', 'Intervention': ['INTERVENTION 1: ', ' NK105', ' received NK105 (65 mg/m^2) on days 1, 8 and 15 of a 28-day cycle', 'INTERVENTION 2: ', ' Paclitaxel', ' received Paclitaxel (80 mg/m^2) on days 1, 8 and 15 of a 28-day cycle'], 'Eligibility': ['Inclusion Criteria:', ' Written inf... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3129e58d-0c16-42a5-90b4-f26e048dfe58 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.